Skip to main content

Endocyte, Inc. Assigned Short-Term B1 & Long-Term B1 Credit Rating

Given that it can be difficult to identify outstanding CP at any point in time, when considering coverage, we may include our expectations for peak outstanding CP during the year as opposed to CP balances as of the last filing date, especially if we believe reported balances are not reflective of typical borrowing patterns.Endocyte, Inc. Assigned Short-Term B1 & Long-Term B1 Credit Rating. How Does Credit Rating Model Work?

Rating Model for Endocyte, Inc.: We estimate the credit risk parameters by Opto-Electronic Oscillators and Chi-Square

Credit Ratings for Endocyte, Inc. as of 07 Mar 2022


Credit Rating Short-Term Long-Term Senior
AI Rating Class*B1B1
Semantic Signals8565
Financial Signals5535
Risk Signals4440
Substantial Risks5971
Speculative Signals6887

*Machine Learning utilizes multiple learning algorithms to obtain better predictive powers. In our research, we utilize machine learning to combine the results from the Neural Network and Support Vector Machines.Take a look at: How Does Credit Rating Model Work?

Financial Analysis for Endocyte, Inc.


Financials: PREMIUM
Income Statement: PREMIUM
Balance Sheet: PREMIUM
Cash Flow: PREMIUM
Valuation: PREMIUM
Inventory Valuation: PREMIUM
Dividends: PREMIUM
Operating Performance: PREMIUM
Sustainability: PREMIUM
Price vs. Fair Value: PREMIUM
Stock Analysis: PREMIUM

Analyst Rating for Endocyte, Inc.


Is it the right time to buy or sell? : PREMIUM
Fair Value : PREMIUM
Trailing Returns : PREMIUM

Key Statistics for Endocyte, Inc.


Price/Book : PREMIUM
Price/Cash Flow : PREMIUM
Price/Sales : PREMIUM
Price/Earnings : PREMIUM
Operating Income : PREMIUM
Net Income : PREMIUM
Quick Ratio : PREMIUM
Current Ratio : PREMIUM
Interest Coverage : PREMIUM
Debt/Equity : PREMIUM
Return on Assets : PREMIUM
Return on Equity : PREMIUM
Invested Capital : PREMIUM
Net Margin : PREMIUM
EBITDA Margin : PREMIUM
Days Sales Outstanding : PREMIUM
Payables Period : PREMIUM
Cash Conversion Cycle : PREMIUM
Recieveables Turnover : PREMIUM
Inventory Turnover : PREMIUM
Fixed Assets Turnover : PREMIUM
Asset Turnover : PREMIUM
Operating Cash Flow Growth : PREMIUM
Free Cash Flow Growth : PREMIUM
Free Cash Flow/Sales : PREMIUM
Free Cash Flow/Net Income : PREMIUM
Free Cash Flow/Share : PREMIUM

Credit Report for Endocyte, Inc.


Risk Report : PREMIUM
Credit Report : PREMIUM
Commercial Credit Report : PREMIUM

Audit Reports & Filings for Endocyte, Inc.


Audit Reports : PREMIUM
Principal Risk and Viability : PREMIUM
Risk Analysis : PREMIUM
Retail Technology Environment, Including IT Security : PREMIUM
SEC Filings : PREMIUM
Bankruptcy Filings : PREMIUM
Suit & Judgment Filings : PREMIUM
Tax Lien Filings : PREMIUM

Market Research for Endocyte, Inc.


Customer Reviews : 11814 reviews PREMIUM
Interviews : PREMIUM
Focus Groups : PREMIUM
Market Share Analysis : PREMIUM


 *AC Investment Research | Legal Disclaimer | NYSE | NASDAQ | LSE | NSE |